Ototoxicity: Unlike other aminoglycosides, the incidence of vestibular and cochlear toxicity is very low. Damage to vestibular function is temporary due to the compensation mechanism.
Usually irreversible cochlear damage is rarely reported. This effect occurs mainly in patients treated with high doses or for the long term therapy.
Other factors also increase the risk of aminoglycoside-induced ototoxicity. Symptoms of aminoglycoside-induced ototoxicity are often transient and can include dizziness, vertigo, tinnitus, hearing noises and hearing loss, the latter usually manifested by reduced sharpness to high pitch.
Rarely reported reactions: headache, lethargy, visual disturbances, disorientation, tachycardia, hypotension, palpitations, thrombocytosis, paresthesia, fluid retention, rash, chills, fever, vomiting, diarrhea.
Possible reactions related to Netilmicin: increased blood sugar, alkaline phosphatase, SGOT or SGPT, bilirubin, other abnormal liver function tests, increased potassium, reduced hemoglobin, white blood cells and platelets, eosinophilia, anemia and increased prothrombin time.
Symptomatic effect: Local reactions such as pain in the administration site, phlebitis and skin reactions. Hypersensitivity reactions such as urticaria and maculopapular rash.
View ADR Monitoring Form